Biology of Blood and Marrow Transplantation · 2018 · 20 citations · 36 references
Life SciencesGeneticsHematologyCancer GeneticsMedical GeneticsStem Cell TransplantationCancer CytogeneticsClinical CytogeneticsMutation AnalysisOncogene MutationsBcr-abl1 Fusion GeneCytogenetic AberrationsCytogenetic AbnormalitiesFlt3 Gene RearrangementKaryotype VariationLeukemia CytogeneticsMutationPrognostic Factors Analysis
Cytogenetic and genetic changes have prognostic significance in acute myelogenous leukemia (AML). In our study, we compared the cytogenetic changes and gene mutations (NPM1, CEBPA, DNMT3A, FLT3-ITD, FLT3-TKD, and C-KIT) with clinical outcomes in 1132 patients with AML enrolled at our center over a 10-year period. A total of 977 patients provided gene mutation data. There were subsets of patients who exhibited mutations in NPM1 (17.9%), CEBPA (16.4%), FLT3-ITD (18.5%), FLT3-TKD (3.9%), DNMT3A (8.6%), and C-KIT (8.8%). A total of 557 patients (49.2%) underwent hematopoietic stem cell transplantation (HSCT) as consolidation therapy. Multivariate analysis identified an adverse karyotype (hazard ratio [HR], 1.48; P = .001), the presence of FLT3-ITD (HR, 1.90; P < .001), and receipt of nonstandard first-line induction chemotherapy (HR, 1.45; P = .003) as significant risk factors for poor overall survival (OS), and the presence of CEBPAmut (HR, .42; P < .001) and receipt of HSCT (HR, .35; P < .001) as prognostic factors for favorable OS. In addition, the presence of FLT3-ITDmut (HR, 2.11; P < .001) was identified as an independent risk factor for poor disease-free survival (DFS), and receipt of HSCT was correlated with improved DFS (HR, .74; P = .046). Compared with chemotherapy as consolidation therapy, HSCT improved the prognosis and overcame the prognostic effect of karyotype from the initial diagnosis; however, the presence of FLT3-ITD or CEBPA mutation can predict prognosis in AML irrespective of HSCT.
36
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations
Medicine, Hematology, Oncology +17
<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia
Timothy J. Ley, Li Ding, Matthew J. Walter et al. · New England Journal of Medicine · 2010 · 2K citations · Full text
David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text
Life Sciences, Hematology, Oncology +16